Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Policy review demands better quality of life data in cancer clinical trials (opens in a new tab)

news-medical.net · 2026-10-01

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredPublished in The Lancet Oncology, the review is led by Ian Tannock, Michael Brundage and Madeline Pe and focuses on adjuvant therapies.View evidenceHide evidence

Why this verdict

The supplied profile supports the focus on adjuvant therapies, but it does not provide enough bibliographic detail at abstract depth to verify publication in The Lancet Oncology or that the named people led the review.

1

Study evidence

Recommend reporting, in trial publications, the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration on a relevant and validated HRQOL scale.

“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer”
Claim 2 of 5Not coveredThe review says clinician-reported toxicity data alone do not fully capture the patient experience and that patient-reported quality of life findings are needed to support informed and shared decision-making.View evidenceHide evidence

Why this verdict

The profile supports the general idea that HRQOL effects are important for treatment decision-making, especially when survival benefits may be small. However, the supplied abstract-level evidence does not specifically verify the story’s statement that clinician-reported toxicity data alone do not fully capture patient experience, nor the specific shared-decision-making framing.

1

Study evidence

Recommend reporting, in trial publications, the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration on a relevant and validated HRQOL scale.

“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer”
Claim 3 of 5SupportedA new policy review from Common Sense Oncology and the European Organisation for Research and Treatment of Cancer calls for quality of life data to play a more central role in clinical trials evaluating adjuvant cancer treatments.View evidenceHide evidence

Why this verdict

The abstract-level profile describes a guidance/recommendations article from Common-Sense Oncology and the EORTC on reporting HRQOL outcomes in randomized trials of adjuvant systemic cancer therapy, including inclusion of HRQOL information in primary trial reports. The story’s framing that the review calls for quality-of-life data to have a more central role is consistent with that evidence.

1

Study evidence

Recommend reporting, in trial publications, the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration on a relevant and validated HRQOL scale.

“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer”
Claim 4 of 5SupportedThe authors recommend that trial reports include not only average quality of life scores, but also the proportion of patients who experience a clinically meaningful deterioration in quality of life and how long that deterioration lasts.View evidenceHide evidence

Why this verdict

The profile explicitly states a recommendation to report the proportion of patients receiving adjuvant therapy who experience prespecified clinically relevant HRQOL deterioration on a validated scale, and to report the duration of that deterioration.

1

Study evidence

Recommend reporting, in trial publications, the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration on a relevant and validated HRQOL scale.

“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer”
Claim 5 of 5SupportedThe recommendations also call for validated patient-reported outcome measures, regular assessment throughout treatment and follow-up, better handling of missing data, and inclusion of quality of life findings in the primary publication of clinical trials.View evidenceHide evidence

Why this verdict

The profile supports recommendations on validated HRQOL scales, assessment of symptoms/functioning/overall HRQOL, appropriate handling of missing data and intercurrent events, and inclusion of HRQOL information in primary trial reports. The story’s wording about regular assessment through treatment and follow-up is broadly consistent with the profile’s references to reporting deterioration during and after treatment and long-term follow-up, though the abstract profile does not give detailed schedules.

1

Study evidence

Recommend reporting, in trial publications, the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration on a relevant and validated HRQOL scale.

“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • HRQOL assessment should cover symptoms, functioning domains, and overall HRQOL, with key outcomes defined by clinicians and patients and supplemented by descriptive reporting across other domains.

    The story mentions validated patient-reported outcome measures and more detailed reporting, but it does not specifically convey the profile’s domain-coverage recommendation or the focus on clinician- and patient-defined key outcomes with descriptive reporting across remaining domains.

    From Expert consensus / guidance development

  • The guidance also recommends appropriate handling of intercurrent events in HRQOL analyses.

    The paper profile identifies intercurrent events as a specific analytical issue, but the story only mentions missing data and does not mention intercurrent events.

    From Expert consensus / guidance development

  • Long-term follow-up reporting should be updated to capture persistent HRQOL deficits.

    The story refers generally to assessment during treatment and follow-up, but it does not specifically report the recommendation for updated long-term follow-up reporting to detect lasting deficits.

    From Expert consensus / guidance development

  • Identifying proportions of patients with adverse HRQOL changes can help determine whether particular patient subgroups are at higher risk.

    This potential use is present in the paper profile but is not covered in the story presentation.

    From Expert consensus / guidance development

5 things the story did carry across
  • The article is guidance/recommendations from Common-Sense Oncology and the EORTC, not a new clinical trial or empirical results paper.
  • The central recommendation is to report HRQOL outcomes in randomized trials of adjuvant systemic cancer therapy, including in primary trial reports.
  • Trial reports should include the proportion of patients with prespecified, clinically relevant HRQOL deterioration on a relevant validated scale.
  • Trial reports should include the duration of HRQOL deterioration during and after treatment completion.
  • The guidance recommends appropriate handling of missing data in HRQOL analyses.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

1

Evidence read

study summary

Lead result

other

1Lead resultotherProvide recommendations for how health-related quality of life (HRQOL) outcomes should be reported in randomized clinical trials of adjuvant systemic cancer therapy (eg, prespecified deterioration thresholds, duration of deterioration, handling missing data/intercurrent events, key domains, and presentation in primary trial reports and long-term follow-up).Expert consensus / guidance developmentExpand

In plain English

Consensus recommendations from Common‑Sense Oncology and the EORTC on how to report health‑related quality of life (HRQOL) outcomes in randomized trials of adjuvant systemic cancer therapy. Key advice includes reporting the proportion of patients with a prespecified, clinically relevant deterioration on validated HRQOL scales, the duration of that deterioration during and after treatment, explicit handling of missing data and intercurrent events, assessment across symptoms, functioning domains, and overall HRQOL, prioritized between‑group comparisons on key outcomes (defined by clinicians and patients) with descriptive reporting across other domains, inclusion of HRQOL in primary trial reports, and updated long‑term follow‑up to detect lasting deficits.

Key findings

  • Recommend reporting, in trial publications, the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration on a relevant and validated HRQOL scale.
  • Recommend reporting the duration of HRQOL deterioration during treatment and after treatment completion.
“Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer”
What this piece can’t prove
  • Article is guidance/recommendations rather than primary empirical research; abstract does not present new trial data.
  • Abstract does not provide operational details (eg, numeric deterioration thresholds, specific validated instruments, statistical methods for missing data/intercurrent events, or exact follow‑up durations).

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer

The Lancet. Oncology · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Selected

Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer

The Lancet. Oncology · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 32 more candidates considered.